Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2025-12-24 @ 4:01 PM
NCT ID:
NCT00732966
Eligibility Criteria:
Inclusion Criteria:
* The study will include 30 patients with the 3 most prevalent alleles of CYP2C9 \*1, \*2 and\*3, 10 patients of each group.
Exclusion Criteria:
* Patients treated with losartan or valsartan prior to their enrollment to the study,
* Patients with BP below 140 systolic or 90 diastolic in an ambulatory 24 hours BP monitoring, acute coronary syndrome during the 6 months previous to the study,
* Renal failure with creatinin levels above 1.5 mg/dL, hyperkalemia (K \> 5 mg/dL),
* Hematologic or solid malignancies or pregnancy.
* Patients will also be excluded from the study if they are known to use one of the drugs inducing or inhibiting the CYP2C9, such as
* rifampicin carbamazepine,
* ethanol,
* phenobarbitone,
* fluconazole,
* amiodarone,
* trimethoprim,
* fluvastatin,
* cimetidine
* chloramphenicol.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00732966
Study Brief:
Protocol Section:
NCT00732966